Digestive and Liver Disease最新文献_第3页

Durable clinical and deep remission with ustekinumab in perianal fistulizing Crohn's disease: A 2-year retrospective real-world cohort study. ustekinumab治疗肛周瘘管性克罗恩病的持久临床和深度缓解：一项为期2年的回顾性现实世界队列研究

IF 3.8 3区医学

Digestive and Liver Disease Pub Date : 2025-09-24 DOI: 10.1016/j.dld.2025.08.091

Qi Chen, Lingbo Li, Can Wang, Lichao Qiao, Minna Wu, Weiming Zhu, Bolin Yang, Yuxia Gong

{"title":"Durable clinical and deep remission with ustekinumab in perianal fistulizing Crohn's disease: A 2-year retrospective real-world cohort study.","authors":"Qi Chen, Lingbo Li, Can Wang, Lichao Qiao, Minna Wu, Weiming Zhu, Bolin Yang, Yuxia Gong","doi":"10.1016/j.dld.2025.08.091","DOIUrl":"https://doi.org/10.1016/j.dld.2025.08.091","url":null,"abstract":"Background and aims: Real-world evidence on ustekinumab for the treatment of perianal fistulizing Crohn's disease (PFCD) remains limited. This study assessed the long-term efficacy of ustekinumab in PFCD.Methods: A total of 143 CD patients with perianal fistulas who initiated ustekinumab therapy were enrolled. Clinical remission was defined as the absence of pain and drainage from fistula tracts, as assessed by physicians. Deep remission was defined as concurrent clinical remission and radiological healing.Results: The study population comprised 143 patients, with a mean age of 28.6 years and a mean number of prior perianal surgeries of 2.5. Overall, 77.6 % of patients had complex fistulas, and 65.7 % experienced prior biologic failure. During a median follow-up of 136.0 (108-156) weeks, 22/143 (18.5 %) patients discontinued ustekinumab therapy. Among patients with active PFCD, clinical remission was achieved in 88/119 (73.9 %) patients. Deep remission was achieved in 40 of 100 evaluable patients (40.0 %), typically 32.1 weeks after clinical remission. Multivariate analysis identified prior exposure to biological agents (hazard ratio [HR] = 0.38, 95 % confidence interval [CI]: 0.20-0.73, P = 0.004) and ileocolonic lesions (HR = 0.47, 95 % CI: 0.23-0.96, P = 0.040) as negative predictors of deep remission. Recurrence was rare (6.3 %), with a 2-year recurrence-free survival rate of 93.4 %.Conclusions: Ustekinumab demonstrates remarkable efficacy in achieving sustained clinical and deep remission in PFCD. Prospective studies are warranted to confirm these findings.","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Author's reply: "Comment on "Diagnostic delay at diagnosis and time-to-treatment influence overall survival of pancreatic cancer patients. 作者回复：关于“诊断延迟和治疗时间影响胰腺癌患者的总生存”的评论。

IF 3.8 3区医学

Digestive and Liver Disease Pub Date : 2025-09-22 DOI: 10.1016/j.dld.2025.08.085

Ruggero Ponz de Leon Pisani, Paolo Giorgio Arcidiacono, Gabriele Capurso

引用次数: 0

Endoscopic features for differentiating sessile serrated lesion with dysplasia or carcinoma in serrated lesions ≥10 mm. ≥10mm的无柄锯齿状病变与发育不良或癌的内镜鉴别特征。

IF 3.8 3区医学

Digestive and Liver Disease Pub Date : 2025-09-22 DOI: 10.1016/j.dld.2025.09.009

Yoshihiro Kishida, Tadakazu Shimoda, Kinichi Hotta, Kenichiro Imai, Sayo Ito, Kazunori Takada, Junya Sato, Tatsunori Minamide, Yoichi Yamamoto, Masao Yoshida, Yuki Maeda, Noboru Kawata, Hirotoshi Ishiwatari, Hiroyuki Matsubayashi, Hiroyuki Ono

{"title":"Endoscopic features for differentiating sessile serrated lesion with dysplasia or carcinoma in serrated lesions ≥10 mm.","authors":"Yoshihiro Kishida, Tadakazu Shimoda, Kinichi Hotta, Kenichiro Imai, Sayo Ito, Kazunori Takada, Junya Sato, Tatsunori Minamide, Yoichi Yamamoto, Masao Yoshida, Yuki Maeda, Noboru Kawata, Hirotoshi Ishiwatari, Hiroyuki Matsubayashi, Hiroyuki Ono","doi":"10.1016/j.dld.2025.09.009","DOIUrl":"https://doi.org/10.1016/j.dld.2025.09.009","url":null,"abstract":"Background and aim: Accurate differentiation of sessile serrated lesion with dysplasia (SSLD) or with carcinoma (SSL+Ca) from hyperplastic polyp (HP) and sessile serrated lesion (SSL) is crucial for appropriate endoscopic management.Methods: This single-center retrospective study included colorectal serrated lesions (≥10 mm) resected between 2017 and 2020 and pathologically diagnosed as HP, SSL, SSLD, or SSL+Ca based on the WHO 5th edition criteria. Characteristic factors associated with SSLD/SSL+Ca and their diagnostic performance were analyzed. Additionally, features of submucosal invasive (pT1) SSL+Ca were examined.Results: Among 498 lesions, 23 (4.6 %) were diagnosed as SSLD/SSL+Ca, with prevalence increasing by size (10-14 mm: 1.2 %, 15-19 mm: 9.2 %, ≥20 mm: 14.3 %). Multivariate analysis identified lesion size ≥15 mm, double elevation, and neoplastic JNET type (2A/2B/3) as significant predictors. A prediction model using these factors demonstrated high diagnostic accuracy (sensitivity 91.3 %, specificity 91.8 %, accuracy 91.8 %, PPV 35.0 %, NPV 99.5 %). In pT1 SSL+Ca, JNET Type 3, Kudo's type V pit pattern, and non-lifting sign were significantly associated.Conclusions: Among HP and SSL ≥10 mm, the prevalence of SSLD/SSL+Ca increased with lesion size. Double elevation and neoplastic JNET type were valuable for diagnosis, aiding appropriate management.","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145130194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Author's reply: Comment on "Severe enterocolitis associated with phosphatidylinositol 3-kinase delta inhibitors: A multicentre cohort study". 作者回复：对“与磷脂酰肌醇3-激酶抑制剂相关的严重小肠结肠炎：一项多中心队列研究”的评论。

IF 3.8 3区医学

Digestive and Liver Disease Pub Date : 2025-09-19 DOI: 10.1016/j.dld.2025.08.089

Aurelien Amiot

引用次数: 0

Author's reply to comments on "Environmental enteropathy and inflammatory bowel disease are not mutually exclusive". 作者对“环境性肠病和炎症性肠病并不相互排斥”评论的回复。

IF 3.8 3区医学

Digestive and Liver Disease Pub Date : 2025-09-19 DOI: 10.1016/j.dld.2025.09.002

Phoebe Hodges, Violet Kayamba, Nicholas M Croft, Paul Kelly

引用次数: 0

Recent developments in diagnosis and management of celiac disease. 乳糜泻诊断和治疗的最新进展。

IF 3.8 3区医学

Digestive and Liver Disease Pub Date : 2025-09-19 DOI: 10.1016/j.dld.2025.09.006

Umberto Volta

引用次数: 0

Artificial Intelligence in Gastroenterology. 胃肠病学中的人工智能。

IF 3.8 3区医学

Digestive and Liver Disease Pub Date : 2025-09-18 DOI: 10.1016/j.dld.2025.09.001

Tommy Rizkala, Cesare Hassan

引用次数: 0

Author's Reply: Comment on "Blue rubber bleb nevus syndrome: A European multicenter cohort study". 作者回复：对“蓝色橡胶水泡痣综合征：一项欧洲多中心队列研究”的评论。

IF 3.8 3区医学

Digestive and Liver Disease Pub Date : 2025-09-18 DOI: 10.1016/j.dld.2025.09.004

Aymeric Becq, Annouk Bisdorff, Jean-Christophe Saurin, Xavier Dray

引用次数: 0

Effects of exercise on body composition, fitness, and blood pressure in overweight or obese patients with MASLD: A systematic review and meta-analysis. 运动对超重或肥胖MASLD患者身体成分、健康和血压的影响：一项系统回顾和荟萃分析

IF 3.8 3区医学

Digestive and Liver Disease Pub Date : 2025-09-18 DOI: 10.1016/j.dld.2025.08.090

Jiu Chen, Peng Gong, Jun Xie

{"title":"Effects of exercise on body composition, fitness, and blood pressure in overweight or obese patients with MASLD: A systematic review and meta-analysis.","authors":"Jiu Chen, Peng Gong, Jun Xie","doi":"10.1016/j.dld.2025.08.090","DOIUrl":"https://doi.org/10.1016/j.dld.2025.08.090","url":null,"abstract":"Objective: To systematically evaluate the effects of exercise on body composition, cardiorespiratory fitness, and blood pressure in overweight or obese patients with metabolic dysfunction-associated steatotic liver disease (MASLD), to provide evidence-based guidance for individualized exercise prescription.Methods: A systematic search was conducted in PubMed, Embase, the Cochrane Library, and Web of Science for randomized controlled trials published from database inception to April 2025. Eligible studies included overweight or obese patients with MASLD, and the intervention consisted of various types of exercise training. The primary outcome measures included body mass index (BMI), body fat percentage, waist circumference, maximal oxygen uptake (VO₂ max), systolic blood pressure (SBP), and diastolic blood pressure (DBP). Meta-analysis was performed using Review Manager version 5.4 and Stata version 16.Results: A total of 26 articles comprising 29 studies and 1123 participants were included. The meta-analysis showed that, exercise interventions were associated with a significant reduction in BMI (SMD = -0.28, P = 0.000) and waist circumference (SMD = -0.41, P = 0.000), while the reduction in body fat percentage did not reach statistical significance (SMD = -0.25, P = 0.061). Regarding blood pressure, exercise significantly decreased DBP (SMD = -0.38, P = 0.000), while the decrease in SBP showed a non-significant trend toward reduction (SMD = -0.26, P = 0.071). In terms of cardiorespiratory fitness, exercise interventions significantly improved VO₂ max (SMD = 0.75, P = 0.000), indicating a notable enhancement in cardiovascular function.Conclusion: Exercise interventions have a positive impact on body composition, cardiorespiratory fitness, and blood pressure in overweight or obese patients with MASLD. The most pronounced effects were observed in the improvement of VO₂ max, waist circumference, and DBP.","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Full Title Page /Editorial Board 完整的标题页/编辑委员会

IF 3.8 3区医学

Digestive and Liver Disease Pub Date : 2025-09-18 DOI: 10.1016/S1590-8658(25)01112-0

引用次数: 0